Table 3.

Diagnostic performances of LR-5/4 of LI-RADS 2018 and definite/probable HCC of KLCA-NCC 2018 for diagnosing HCC on ECA-MRI and HBAMRI

	LR-5/4 of LI-RADS 2018 (95% CI)	Definite/probable HCC of KLCA-NCC 2018 (95% CI)	P-value*
ECA-MRI all (n=86)
Sensitivity	87.1 (78.8–95.4)	83.9 (74.7–93.0)	0.313
Specificity	87.5 (74.3–100.0)	91.7 (80.6–100.0)	0.307
ECA-MRI 10–19 mm (n=28)
Sensitivity	94.1 (82.9–100.0)	76.5 (56.3–96.6)	0.056
Specificity	100.0 (100.0–100.0)	100.0 (100.0–100.0)	>0.999
ECA-MRI ≥20 mm (n=58)
Sensitivity	84.4 (73.9–95.0)	86.7 (76.7–96.6)	0.312
Specificity	76.9 (54.0–99.8)	84.6 (65.0–100.0)	0.298
HBA-MRI all (n=266)
Sensitivity	88.1 (83.6–92.5)	85.6 (80.7–90.4)	0.057
Specificity	80.0 (70.3–89.7)	92.3 (85.8–98.8)	0.003
HBA-MRI 10–19 mm (n=104)
Sensitivity	87.1 (78.8–95.4)	82.3 (72.8–91.8)	0.076
Specificity	73.8 (60.5–87.1)	92.9 (85.1–100.0)	0.002
HBA-MRI ≥20 mm (n=162)
Sensitivity	88.5 (83.2–93.8)	87.1 (81.5–92.6)	0.316
Specificity	91.3 (79.8–100.0)	91.3 (79.8–100.0)	>0.999

LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center; ECA, extracellular contrast agent; MRI, magnetic resonance imaging; HBA, hepatobiliary agent; CI, confidence interval.

^*P-values between LR-5/4 of LI-RADS 2018 and definite/probable HCC of KLCA-NCC 2018 by using the generalized estimating equation method.